Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors or Chemotherapy in Luminal B/HER2-negative Breast Cancer (DAPATH)
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
Compare the efficacy and safety of Dalpiciclib combined with aromatase inhibitors versus
chemotherapy as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer, and explore
the predictive biomarkers of the response to the two neoadjuvant therapies.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University